505 related articles for article (PubMed ID: 17822493)
1. Pemphigus vulgaris and pemphigus foliaceus: similar prognosis?
Zaraa I; Mokni M; Hsairi M; Boubaker S; Sellami M; Zitouni M; Makni S; Dhahri AB
Int J Dermatol; 2007 Sep; 46(9):923-6. PubMed ID: 17822493
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of sensitivity and specificity of enzyme-linked immunosorbent assay (ELISA) for detecting antidesmoglein 1 and 3 in Thai patients with pemphigus vulgaris and foliaceus.
Kulkollakarn S; Wattanakrai P; Vachiramon V; Chalidapongse P
J Med Assoc Thai; 2008 Nov; 91(11):1663-8. PubMed ID: 19127786
[TBL] [Abstract][Full Text] [Related]
3. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus.
Abasq C; Mouquet H; Gilbert D; Tron F; Grassi V; Musette P; Joly P
Arch Dermatol; 2009 May; 145(5):529-35. PubMed ID: 19451496
[TBL] [Abstract][Full Text] [Related]
4. [Transition from pemphigus vulgaris to pemphigus foliaceus: a case report].
Lévy-Sitbon C; Reguiaï Z; Durlach A; Goeldel AL; Grange F; Bernard P
Ann Dermatol Venereol; 2013 Dec; 140(12):788-92. PubMed ID: 24315225
[TBL] [Abstract][Full Text] [Related]
5. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.
Marazza G; Pham HC; Schärer L; Pedrazzetti PP; Hunziker T; Trüeb RM; Hohl D; Itin P; Lautenschlager S; Naldi L; Borradori L;
Br J Dermatol; 2009 Oct; 161(4):861-8. PubMed ID: 19566661
[TBL] [Abstract][Full Text] [Related]
6. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
7. Pemphigus vulgaris: recent advances in our understanding of its pathogenesis.
Femiano F
Minerva Stomatol; 2007 Apr; 56(4):215-23. PubMed ID: 17452959
[TBL] [Abstract][Full Text] [Related]
8. Desmoglein 1 and 3 enzyme-linked immunosorbent assay in Iranian patients with pemphigus vulgaris: correlation with phenotype, severity, and disease activity.
Daneshpazhooh M; Chams-Davatchi C; Khamesipour A; Mansoori P; Taheri A; Firooz A; Mortazavi H; Esmaili N; Dowlati Y
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1319-24. PubMed ID: 17958835
[TBL] [Abstract][Full Text] [Related]
9. Value of direct immunofluorescence in predicting remission in pemphigus vulgaris.
Balighi K; Taheri A; Mansoori P; Chams C
Int J Dermatol; 2006 Nov; 45(11):1308-11. PubMed ID: 17076711
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations.
Caldarola G; Kneisel A; Hertl M; Feliciani C
Eur J Dermatol; 2008; 18(4):440-3. PubMed ID: 18573719
[TBL] [Abstract][Full Text] [Related]
11. A comparison of anti-desmoglein antibodies and indirect immunofluorescence in the serodiagnosis of pemphigus vulgaris.
Zagorodniuk I; Weltfriend S; Shtruminger L; Sprecher E; Kogan O; Pollack S; Bergman R
Int J Dermatol; 2005 Jul; 44(7):541-4. PubMed ID: 15985020
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the development and prognosis of pemphigus vulgaris and seborrheic pemphigus].
Dehen L; Crickx B; Grossin M; Belaïch S
Ann Dermatol Venereol; 1993; 120(12):874-8. PubMed ID: 8074345
[TBL] [Abstract][Full Text] [Related]
13. [A clinical analysis of 64 cases of pemphigus].
He Z; Wang B; Yu B
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Apr; 20(2):144-7. PubMed ID: 11367721
[TBL] [Abstract][Full Text] [Related]
14. Three cases of transition from pemphigus vulgaris to pemphigus foliaceus confirmed by desmoglein ELISA.
Ng PP; Thng ST
Dermatology; 2005; 210(4):319-21. PubMed ID: 15942219
[TBL] [Abstract][Full Text] [Related]
15. Desmoglein ELISA in the diagnosis of pemphigus and its correlation with the severity of pemphigus vulgaris.
Mortazavi H; Shahdi M; Amirzargar AA; Naraghi ZS; Valikhani M; Daneshpazhooh M; Vasheghani-Farahani A; Sedaghat M; Chams-Davatchi C
Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):53-6. PubMed ID: 19279360
[TBL] [Abstract][Full Text] [Related]
16. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission.
Daneshpazhooh M; Zafarmand Sedigh V; Balighi K; Hosseini SH; Ramezani A; Kalantari MS; Ghandi N; Ghiasi M; Nikoo A; Chams-Davatchi C
J Am Acad Dermatol; 2016 Jun; 74(6):1160-5. PubMed ID: 26896293
[TBL] [Abstract][Full Text] [Related]
17. Correlation of immunological profile with phenotype and disease outcome in pemphigus.
Herrero-González JE; Iranzo P; Benítez D; Lozano F; Herrero C; Mascaró JM
Acta Derm Venereol; 2010 Jul; 90(4):401-5. PubMed ID: 20574606
[TBL] [Abstract][Full Text] [Related]
18. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
Sami N; Qureshi A; Ahmed AR
Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
[TBL] [Abstract][Full Text] [Related]
19. [Juvenile pemphigus vulgaris].
Janisson-Dargaud D; Reguiaï Z; Perceau G; Eschard C; Bernard P
Ann Dermatol Venereol; 2008 Dec; 135(12):843-7. PubMed ID: 19084695
[TBL] [Abstract][Full Text] [Related]
20. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
Feldman RJ; Christen WG; Ahmed AR
Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
